JP2024503441A5 - - Google Patents
Info
- Publication number
- JP2024503441A5 JP2024503441A5 JP2023542581A JP2023542581A JP2024503441A5 JP 2024503441 A5 JP2024503441 A5 JP 2024503441A5 JP 2023542581 A JP2023542581 A JP 2023542581A JP 2023542581 A JP2023542581 A JP 2023542581A JP 2024503441 A5 JP2024503441 A5 JP 2024503441A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- optionally substituted
- cells
- subject
- saturated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163139732P | 2021-01-20 | 2021-01-20 | |
| US63/139,732 | 2021-01-20 | ||
| PCT/US2022/012954 WO2022159475A1 (en) | 2021-01-20 | 2022-01-19 | Nanomaterials comprising an ionizable lipid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024503441A JP2024503441A (ja) | 2024-01-25 |
| JP2024503441A5 true JP2024503441A5 (cg-RX-API-DMAC10.html) | 2025-01-28 |
Family
ID=82549746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023542581A Pending JP2024503441A (ja) | 2021-01-20 | 2022-01-19 | イオン化可能な脂質を含むナノ材料 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240115511A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4281064A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024503441A (cg-RX-API-DMAC10.html) |
| CN (1) | CN116963729A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022210317A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3203741A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022159475A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7600208B2 (ja) | 2019-07-29 | 2024-12-16 | ジョージア テック リサーチ コーポレイション | 拘束された脂質を含むナノ材料およびその使用 |
| CN115175894B (zh) | 2020-01-09 | 2024-09-06 | 盖德治疗有限责任公司 | 纳米材料 |
| CZ310613B6 (cs) | 2020-09-23 | 2026-01-28 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Lipidoidy pro transfekci nukleových kyselin a jejich použití |
| EP4281080A4 (en) | 2021-01-20 | 2025-09-24 | Beam Therapeutics Inc | NANOMATERIALS COMPRISING A BIODEGRADABLE ELEMENT |
| CN116761888A (zh) | 2021-01-20 | 2023-09-15 | 比姆医疗股份有限公司 | 纳米材料 |
| CZ310443B6 (cs) | 2021-07-19 | 2025-06-25 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití |
| WO2024238658A2 (en) * | 2023-05-15 | 2024-11-21 | The Trustees Of The University Of Pennsylvania | Delivery vehicle for targeted delivery to cardiomyocytes |
| EP4719352A1 (en) | 2023-05-31 | 2026-04-08 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| AU2024408317A1 (en) * | 2023-12-18 | 2026-06-11 | Lifemine Therapeutics, Inc. | Triester compounds and methods of use thereof |
| US20250381150A1 (en) | 2024-03-08 | 2025-12-18 | Genzyme Corporation | Lipid nanoparticles |
| WO2026003582A2 (en) | 2024-06-27 | 2026-01-02 | Axelyf ehf. | Lipids and lipid nanoparticles |
| WO2026030375A2 (en) | 2024-07-30 | 2026-02-05 | Genzyme Corporation | Lipid nanoparticles and methods of manufacture and use thereof |
| WO2026142951A1 (en) | 2024-12-23 | 2026-07-02 | Genzyme Corporation | Pharmaceutical system |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2550449B1 (fr) * | 1983-08-12 | 1986-01-31 | Commissariat Energie Atomique | Agents de relaxation specifiques d'organes ou de pathologies, utilisables pour modifier les contrastes en imagerie medicale par resonance magnetique nucleaire |
| JP2012505855A (ja) * | 2008-10-17 | 2012-03-08 | ユニヴェルシテ リブレ ド ブリュッセル | 抗癌治療における使用のためのジバニロイルおよびトリバニロイル誘導体 |
| ES2887254T3 (es) * | 2013-03-08 | 2021-12-22 | Novartis Ag | Lípidos y composiciones lipídicas para el suministro de agentes activos |
| BR112019025104A2 (pt) * | 2017-05-30 | 2020-06-23 | Glaxosmithkline Biologicals S.A. | Método de fabricar um sistema de entrega não viral, sistema de entrega não viral, e, composição |
| KR102710962B1 (ko) * | 2017-07-04 | 2024-09-27 | 주식회사 인투셀 | 절단성 링커를 포함하는 화합물 및 이들의 용도 |
| CN116761888A (zh) * | 2021-01-20 | 2023-09-15 | 比姆医疗股份有限公司 | 纳米材料 |
-
2022
- 2022-01-19 CA CA3203741A patent/CA3203741A1/en active Pending
- 2022-01-19 JP JP2023542581A patent/JP2024503441A/ja active Pending
- 2022-01-19 CN CN202280009720.7A patent/CN116963729A/zh active Pending
- 2022-01-19 EP EP22743092.3A patent/EP4281064A4/en active Pending
- 2022-01-19 WO PCT/US2022/012954 patent/WO2022159475A1/en not_active Ceased
- 2022-01-19 AU AU2022210317A patent/AU2022210317A1/en active Pending
-
2023
- 2023-07-12 US US18/220,867 patent/US20240115511A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024505449A5 (cg-RX-API-DMAC10.html) | ||
| JP2024502948A5 (cg-RX-API-DMAC10.html) | ||
| JP2025501731A5 (cg-RX-API-DMAC10.html) | ||
| JP2024508347A5 (cg-RX-API-DMAC10.html) | ||
| JP2024502954A5 (cg-RX-API-DMAC10.html) | ||
| JP7654724B2 (ja) | 治療剤の細胞内送達のための化合物および組成物 | |
| JP2025500824A5 (cg-RX-API-DMAC10.html) | ||
| RU2175337C2 (ru) | Полинуклеотидные композиции | |
| CA3113436A1 (en) | Compounds and compositions for intracellular delivery of therapeutic agents | |
| CN119684140A (zh) | 纳米材料 | |
| CN120423969A (zh) | 用于治疗剂的细胞内递送的支链尾端脂质化合物和组合物 | |
| WO2022168085A1 (en) | Lipids suitable for nucleic acid delivery | |
| EP3661563A1 (en) | Biomimetic nanomaterials and uses thereof | |
| KR20120046099A (ko) | 섬유화를 억제하고 섬유화 질병을 치료하는 방법 | |
| WO2017190145A1 (en) | Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis | |
| US6344576B1 (en) | Phospholipid-analogous compounds | |
| Mancino et al. | RNA therapies for musculoskeletal conditions | |
| EP4603475A1 (en) | Amino lipid compound and lipid nanoparticle for delivering bioactive ingredient | |
| US8501680B2 (en) | Antagonists against interaction of PF4 and RANTES | |
| EP0652755B1 (en) | Therapeutic use of phosphoryl-l-serine-n-acyl-sphingosine | |
| FR3110836A1 (fr) | Utilisation de NMN pour réduire l’immunodépression et l’immunosénescence | |
| CN121729406A (zh) | 具有提高的稳定性的可生物降解的氨基甲酸酯脂质 | |
| JP2025540229A (ja) | 複数の第三級アミン構造を含むビスホスホリルアミド化合物、及びその組成物と使用 | |
| JP7842738B2 (ja) | バイオインスパイアード脂質誘導体及びその使用 | |
| JP5638958B2 (ja) | ウイルス性肝炎におけるsLDLR |